NTLA Q3 2021 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-67.6% YoY

Gross Profit

-$53M-739.6% margin

Operating Income

-$72M-999.3% margin

Net Income

-$72M-994.5% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$70M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$228M

Stockholders' Equity

$1.1B

Cash & Equivalents

$335M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$22M	-67.6%
Gross Profit	-$53M	-$18M	-203.8%
Operating Income	-$72M	-$28M	-156.2%
Net Income	-$72M	-$28M	-157.3%